Boston Scientific Corporation (NYSE:BSX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Boston Scientific Corporation (NYSE:BSX) have been assigned an average rating of “Buy” from the twenty-five brokerages that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $123.7727.

Several equities research analysts recently commented on the stock. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Robert W. Baird lifted their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. BTIG Research reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a report on Friday, November 21st. Wells Fargo & Company raised their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Finally, Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd.

Boston Scientific Trading Down 0.5%

NYSE:BSX opened at $98.52 on Thursday. Boston Scientific has a 1 year low of $85.98 and a 1 year high of $109.50. The stock has a market cap of $146.04 billion, a P/E ratio of 52.68, a P/E/G ratio of 2.03 and a beta of 0.67. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock has a 50-day simple moving average of $99.29 and a 200-day simple moving average of $102.17.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the business earned $0.63 earnings per share. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This represents a 21.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 143,095 shares of company stock worth $14,228,950 in the last 90 days. 0.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Boston Scientific by 0.8% during the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. State Street Corp raised its position in Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Geode Capital Management LLC raised its position in Boston Scientific by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock worth $3,466,320,000 after buying an additional 622,602 shares during the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific in the 2nd quarter worth $2,089,937,000. Finally, Invesco Ltd. boosted its holdings in shares of Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock valued at $1,656,131,000 after acquiring an additional 111,826 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.